// App-Quantinova.ai

e16536 : Predictors of radiologic progression free survival (rPFS) during abiraterone acetate (AA) treatment in a randomized phase II study of AA maintenance in combination with docetaxel (D) after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): ABIDO-SOGUG trial.

Researchers

Presenter

  • Daniel Castellano

Principal Investigators

  • Maria Jose Mendez-Vidal

  • Javier Puente

  • M Isabel Saez

  • Albert Font Pous

  • Ignacio Duran

  • Carmen Santander

  • Alfredo Sanchez-Hernandez

  • Jose Angel Arranz Arija

  • Teresa Alonso

  • Begona Mellado

  • Martin Lazaro Quintela

  • Aranzazu Gonzalez del Alba

  • Emilio Esteban

  • Pablo Maroto

  • Javier Cassinello

  • Miguel Angel Climent

Medical Centers

  • Medical Oncology Department. Hospital 12 de Octubre, Madrid, Spain

  • Hospital Universitario Reina Sofia, Cordoba, Spain

  • Hospital Universitario Clinico San Carlos, Madrid, Spain

  • CRIS Cancer Foundation Prostate Cancer Research Group, Institute of Biomedical Research in Malaga/ CNIO-IBIMA Genitourinary Cancer Research Unit, H Universitarios Virgen de la Victoria y Regional de Malaga, Malaga, Spain

  • Institut Catala d'Oncologia, Hospital Universitario German Trias i Pujol, Badalona, Spain

  • Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, Spain

  • H. Universitario Miguel Servet, Zaragoza, Spain

  • Hospital Provincial Castellon, Castellon, Spain

  • Medical Oncology Service, Hospital General Universitario Gregorio Maranon, Madrid, Spain

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Complejo Hospital Universitario de Vigo, Vigo, Spain

  • Son Espases University Hospital, Palma De Mallorca, Spain

  • Hospital Universitario Central de Asturias, Oviedo, Spain

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Hospital Universitario de Guadalajara, Guadalajara, Spain

  • Instiuto Valenciano de Oncologia, Valencia, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • II

Study Id's

  • NCT02036060

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved